Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/20—Interleukins [IL]
  • A61K38/2066—IL-10
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
  • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
  • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
  • A61K40/31—Chimeric antigen receptors [CAR]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
  • A61K40/32—T-cell receptors [TCR]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/42—Cancer antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/42—Cancer antigens
  • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
  • A61K40/4203—Receptors for growth factors
  • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/42—Cancer antigens
  • A61K40/4271—Melanoma antigens
  • A61K40/4273—Glycoprotein 100 [Gp100]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
  • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/5428—IL-10
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
  • A61K2239/57—Skin; melanoma
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/52—Constant or Fc region; Isotype
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

• the present invention relates generally to the field of anti-cancer therapy, in particular co agents useful in anti-cancer immunotherapy such as adoptive T-cell transfer (ACT) immunotherapy and immune check-point blockades.
• ACT adoptive T-cell transfer
• Adoptive T-cell transfer (ACT) immunotherapy has produced stunning clinical results recently. Unlike traditional chemo- and radiotherapy, immunotherapy actives host immune system to attack malignancies, and this potentially offers long-term protection from recurrence with less toxicity in comparison to conventional chemo- and radiation therapy.
• adoptive CD8+ T cell therapy large numbers of tumor-specific T cells are sourced from patients and expanded in vitro and infused back to patients ⁇ Jiang et al, 2019, Cancer Lett., 10;462:23-32; Levine et al, 2017 Cell Therapy. Mol. Ther. - Methods Clin. Dev. 4, 92 101).
• T cells can be expanded from naturally-induced tumor-specific CD8+ T cells isolated from tumor infiltrating lymphocytes (TILs) or genetically-modified autologous circulating CD8+ T cells.
• the engineered T cells expressed tumor-specific antigen receptors including chimeric antigen receptors (CARs) and T cell receptors (TCRs), prepared from cultured T cell clones, respectively.
• CARs chimeric antigen receptors
• TCRs T cell receptors
• the most successful ACT, anti-CD 19 chimeric antigen receptor T (CAR-T) cell therapy directed against B cell lymphoma, is already approved for use based on evidence of efficacy ⁇ June et al, 2018, Science 359, 1361 1365).
• TILs tumor-infiltrating lymphocytes
• Interleukine-10 a member of the IL-10 family cytokines is generally considered immunosuppressive as it reduces tissue damage caused by uncontrolled inflammatory responses ⁇ Moore et ah, 2001, Annu. Rev. Immunol. 19, 683 765).
• Heterologous multimeric proteins comprising cetuximab and two IL-10 molecules covalently linked by a polypeptide linker (CmAb-(IL-10) 2 ) have been developed to prolong half-live and allow tumor targeted delivery of IL-10 ⁇ Qiao etal.,2019, Cancer Cell, 35(6), 901-915). Therefore, there is an urgent need for safe tools for the metabolic reprogramming of adoptively transferred T cells that can be combined with ACT to induce durable cures for solid tumors.
• CmAb-(IL-10) 2 polypeptide linker
• the present invention is based on the unexpected findings that metabolic reprograming of tumor infiltration lymphocytes with a fusion protein IL-10/Fc markedly enhanced the efficacy of ACT against established solid tumors in syngeneic tumor bearing mouse models. It has been observed that surprisingly a fusion protein IL-10/Fc of the invention selectively expands tumor specific PD-1+TIM-3+CD8+ T cells in the tumor microenvironment, which indicates that the fusion protein had little systemic influence on other cell subsets with good safety profile compared to IL-12 or IL-15 based therapies ⁇ Wang et ah, 2017, Nat. Commun., 8, 1 15; Momin et ah, 2019, Sci. Transl. Med.
• the invention provides a Fc fusion protein for use in the prevention and/or treatment of a cancer, wherein said Fc fusion protein is a homodimer of two polypeptides, each comprising (i) an immunoglobulin IgG Fc domain and (ii) a heterologous polypeptide a comprising a sequence of a human IL-10 or a variant thereof, wherein the heterologous polypeptide is covalently linked to the N-terminus or the C-terminus of the Fc domain by a polypeptide linker (e.g. a flexible hinge) and the two heterologous polypeptides are non-covalently assembled in a homodimer.
• a polypeptide linker e.g. a flexible hinge
• a pharmaceutical composition comprising at least one Fc fusion protein according to the invention and a pharmaceutically acceptable carrier, diluent or excipient thereof and at least one agent useful in anti-cancer immunotherapy.
• the invention provides a use of a Fc fusion protein according to the invention for the preparation of a pharmaceutical composition for the prevention and/or treatment of a cancer.
• the invention provides a method of preventing or treating a cancer, said method comprising administering in a subject in need thereof a therapeutically effective amount of at least one Fc fusion protein of the invention.
• the invention provides a method of inducing immunity or restoring of responsiveness to immunotherapy, in a subject, said method comprising administering a Fc fusion protein of the invention in a subject in need thereof in combination with an immune check-point blockade therapy.
• Figure 1 represents which IL-10/Fc promotes OXPHOS of CD8+ T-cells during priming phase and enhances T-cell proliferation
• IL-10/Fc a fusion protein of the invention as a homodimer described therein
• IL-10/Fc comprising two polypeptides, each comprising (i) an immunoglobulin IgG Fc domain and (ii) a heterologous polypeptide a comprising a sequence of a human IL-10 or a variant thereof, wherein each heterologous polypeptide is covalently linked to the N-terminus or the C-terminus of the Fc domain by a polypeptide linker L and the two IL-10 polypeptides are non-covalently assembled in a homodimer (dotted lines between the heterologous IL-10 polypeptides); right: SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) of recombinant human IL-10 and I
• Figure 2 represents IL-10/Fc reprograms T cells metabolism upon TCR stimulation through a pyruvate-dependent manner
• Pmel-1 mouse CD8 + T cells were activated by stimulation with hgplOO peptides for 3 days and rested for another 4 days, followed by co-culture with B16F10 mouse melanoma cells for further 2 days, with or without the presence of IL-10/Fc.
• Control Pmel-1 CD8 T cells were kept in resting phase without B16F10 cells.
• Representative OCR trace and representative ECAR trace for CD8 + T cells isolated from the co-culture (b) Statistical analysis of maximal OCR from (a) (c) Statistical analysis of maximal ECAR from (a) (d) Ratios of OCR/EC AR from (c) and (d).
• Figure 3 represents IL-10/Fc potentiates adoptive T cells therapy to eradicate established highly aggressive mouse melanoma tumors
• (f) Experimental scheme for Pmel CD8 + T cells ACT and IL-10/Fc combination therapy for mouse B16F10 melanoma model with reduced doses
• Figure 4 represents IL-10/Fc combines with adoptive T cells therapy to eradicate established tumors in multiple syngeneic tumor mouse models
• Tumor growth was monitored for mice treated as in Fig 3(a).
• OVA-specific OT-I CD8 + T cells were applied as ACT in this model.
• Experimental schedule was same as in Fig 3(a.) Tumor growth was monitored (e) Survival plot of mice treated as in (d). (1) 1 x 10 6 MC38-HER2 mouse colon cancer cells were subcutaneously inoculated on C57BL/6J mice. HER2-CAR-T cells were applied as ACT in this model. Experimental schedule was same as in Fig 3(a.) Tumor growth was monitored (g) Survival plot of mice treated as in (f). Data represent at least three independent experiments for (a) and (b). Data from (c) are the collection of two independent experiments. Error bars indicate SEMs.
• FIG. 5 shows IL-10/Fc enhances anti -tumor immunity
• a Experimental scheme for flow cytometry mechanism study in mouse B16F10 melanoma model. Mice were sacrificed on day 14 and TILs were analyzed by flow cytometry
• b Total CD45.2 + leukocytes and NK cells and CDllc + dendritic cells (DCs) density in tumor
• DCs CDllc + dendritic cells
• Tregs Foxp3 + regulatory T cells
• B16F10 TILs were analyzed by flow cytometry as in Fig 5(a).
• CD8 + T cell counts (j) and B16F10 cell killing efficiency (k) were evaluated by flow cytometry.
• Figure 7 shows IL-10/Fc potentiates checkpoint blockade therapy to eradicate established mouse colon tumors
• a-PD-1 and IL-10/Fc combination therapy for mouse CT26 colon cancer model. 3 x 10 5 CT26 mouse colon cancer cells were subcutaneously inoculated on BALB/c mice. a-PD-1 antibody (RMP-14) was given every three days as control
• RMP-14 a-PD-1 antibody
• c Tumor growth was monitored for mice treated as in (a)
• a “Fc fusion protein” relates to a Fc fusion protein (homodimer) comprising the sequence of a human IL-10 or a variant thereof and an IgG Fc fragment covalently linked together though a flexible hinge.
• the IgG Fc fragment can be a Fc fragment from IgGl, IgG2, IgG3 or IgG4 isoform.
• IgG Fc fragments can be mutated for decreasing the antibody-dependent cell-mediated cytotoxicity (ADCC) such as described in Czajkowsky et ah, 2012, EMBO Mol.
• ADCC antibody-dependent cell-mediated cytotoxicity
• point mutations can be introduced in IgGl Fc domains as described in Armour et al, 1999, Eur. J. Immunol. 29, 2613 2624 or Steele et al, 1995, J. Immunol. 154, 5590 5600 to generate a non-cytolytic IgGl Fc domain.
• At least three mutations selected from L234V, L235A and P331S in IgGl Fc domain of SEQ ID NO: 2 is made.
• At least two mutations selected from A330S and P331S in IgG2 Fc domain of SEQ ID NO: 5 is made.
• At least one mutation P329G in IgG4 Fc domain of SEQ ID NO: 11 is made.
• a “human IL-10 or a variant thereof’ include sequences comprising the sequence of native human IL-10 and variants thereof such as described in Mumm et al, 2011, Cancer Cell, 20, 781 796; Guo, et al, 2012, Protein Expr. Purif., 83, 152 156 (2012); Zheng et al, 1997, J. Immunol., 158, 4507 13; Qiao et al, 2019, Cancer Cell 35, 901 915. e4.
• Fc fusion proteins of the invention can be modified for extending its half-life in vivo by standard strategies, including pegylation (e.g.
• a “flexible hinge” useful in the context of the invention can peptidic or non- peptidic.
• the flexible hinge is of peptidic nature it generally contains between about 3 to 20 amino acids.
• suitable hinge of the invention can be selected among those described in Klein et al, 2014, Protein Eng. Des. Sel. 27, 325 330.
• Non-peptidic flexible hinges can be selected among linkers described in Capon et al, 2011, Proc. Japan Acad. Ser. BPhys. Biol. Sci., 87, 603 616.
• a “GS” linker refers to any peptidic linker comprising amino acids selected from G and S or a combination thereof combined with CPPCP domain (SEQ ID NO: 15), such as GGSCPPCP (SEQ ID NO: 16), GGGGSCPPCP (SEQ ID NO: 17), GGGGSGGGGSCPPCP (SEQ ID NO 14), or longer linker.
• a GS linker has a length from about 3 to about 50 amino acids such as about 3 to 20, for example from 5 to about 15.
• variant applied to a peptide or polypeptide, as referred to herein means a peptide or polypeptide substantially homologous to the referenced peptide sequence, but which has at least one amino acid different from that of the referenced sequence because of one or more amino acid deletion, insertion and/or substitution.
• substantially homologous means a variant amino acid sequence which is identical to the referenced peptide sequence except for the deletion, insertion and/or substitution of 1, 2, 3, 4, 5 or 6 amino acid residues.
• a variant amino acid sequence is identical to the referenced peptide sequence except for the deletion and/or conservative substitution of 1, 2, 3, 4, 5 or 6 amino acid residues.
• a variant may comprise a sequence having at least one conservatively substituted amino acid, meaning that a given amino acid residue is replaced by a residue having similar physicochemical characteristics.
• conservative substitutions include substitution of one aliphatic residue for another, such as lie, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gin and Asn.
• Amino acid hydrophobicity can be found on the basis of known scales such as Kyte, et al, 1982, ./. Mol.
• a "conservative amino acid substitution” may involve a substitution of a native amino acid residue with a non-native residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. Exemplary amino acid substitutions are presented in Table 1 below.
• variant also includes a peptide or polypeptide substantially homologous to the referenced peptide sequence, but which has an amino acid sequence different from that of the referenced sequence because one or more amino acids have been chemically modified or substituted by amino acids analogs.
• non-natural residues can be introduced to enhance the pharmacological properties of peptide-based therapeutics ( Geurink et al, 2013, J. Med. Chem., 56, 1262; Rand et al, 2012, Med. Chem. Commun, 3, 1282).
• Table 1 Table 1
• sequence of the invention can be optionally acetylated at the N-terminus and/or amidated at the C-terminus. According to another particular embodiment, the sequence of the invention can be optionally pegylated.
• anti-cancer immunotherapy refers to anti-cancer therapeutic strategies to effector activate immune cells which encompasses adoptive cellular therapy (ACT) and strategies to neutralize immunosuppressor mechanisms such as agents, in particular antibodies, against immune-checkpoint molecules such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1) such as described in Weiden etal, 2018, Nat. Rev. Immunol., 18, 212 219.
• ACT adoptive cellular therapy
• immunosuppressor mechanisms such as agents, in particular antibodies, against immune-checkpoint molecules such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1) such as described in Weiden etal, 2018, Nat. Rev. Immunol., 18, 212 219.
• CTL-4 cytotoxic T lymphocyte-associated protein 4
• PD1 programmed cell death protein 1
• ACT immunotherapy refers to a therapeutic technique where T-cells are collected from a patient's blood or tumour and grown in the laboratory. Once there are enough T-cells, they are given back to the patient to help their immune system to fight cancer cells. Examples of ACT immunotherapies are listed under Fan et ah, 2018, Theranostics, 8(20): 5784 5800 ; Rosenberg et al, 2008, Nat. Rev. Cancer 8, 299 308; Wang et al, 2014, Immunotherapy 6, 1265 1278.
• an “immune checkpoint inhibitor” refers to agents that antagonize or inhibit immune-checkpoint molecules and those can be selected from example among PD-1 inhibitors, PD-L1 inhibitors or CTLA-4 inhibitors or LAG-3 inhibitors such as described in Pardoll et al, 2012, Nat. Rev. Cancer 12, 252 264; Lee et al, 2019, Molecules 4, 1 16.
• PD-1 inhibitors include anti -PD-1 monoclonal antibodies, such as Keytruda and Opdivo such as described in Lee etal, 2019, supra.
• PD-L1 inhibitors include PD-L1 antibodies and PD-l-Ig fusion protein such as described in Pardoll et al, 2012, supra.
• CTLA-4 inhibitors include anti-CTLA-4 monoclonal antibodies, such as Ipilimumab and Tremelimumab such as described in Pardoll et al, 2012, supra.
• treatment and “treating” and the like generally mean obtaining a desired pharmacological and physiological effect.
• the effect may be prophylactic in terms of preventing or partially preventing a disease, symptom or condition thereof and/or may be therapeutic in terms of a partial or complete cure of a disease, condition, symptom or adverse effect attributed to the disease.
• treatment covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it such as a preventive early asymptomatic intervention; (b) inhibiting the disease, i.e., arresting its development; or relieving the disease, i.e., causing regression of the disease and/or its symptoms or conditions such as improvement or remediation of damage.
• the methods, uses, formulations and compositions according to the invention are useful for the prevention and/or treatment of a cancer.
• solid tumour cancer includes, lung cancer (small cell and non-small cell), breast cancer, ovarian cancer, cervical cancer, uterus cancer, head and neck cancer, glioblastoma, hepatocellular carcinoma, colon cancer, rectal cancer, colorectal carcinoma, kidney cancer, prostate cancer, gastric cancer, bronchus cancer, pancreatic cancer, urinary bladder cancer, hepatic cancer and brain cancer or skin cancer, in particular melanoma.
• mammals contemplated by the present invention include human, primates, domesticated animals such as cattle, sheep, pigs, horses, laboratory rodents, other pets and the like.
• the term "effective amount” as used herein refers to an amount of at least one compound of the invention or a pharmaceutical formulation thereof according to the invention that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought.
• the effective amount is a "therapeutically effective amount” for the alleviation of the symptoms of the disease or condition being treated.
• the effective amount is a "prophylactically effective amount” for prophylaxis of the symptoms of the disease or condition being prevented.
• the term also includes herein the amount of compound of the invention sufficient to reduce the progression of the disease, notably to reduce or inhibit the progression of a cancer disorder and thereby elicit the response being sought (i.e. an "effective amount").
• an effective amount can be used to inhibit the growth of cancer cells, i.e. any slowing of the rate of cancer cell proliferation and/or migration, arrest of cancer cell proliferation and/or migration, or killing of cancer cells, such that the rate of cancer cell growth is reduced in comparison with the observed or predicted rate of growth of an untreated control cancer cell.
• the term "inhibits growth” can also refer to a reduction in size or disappearance of a cancer cell or tumor, as well as to a reduction in its metastatic potential.
• such an inhibition at the cellular level may reduce the size, defer the growth, reduce the aggressiveness, or prevent or inhibit metastasis of a cancer in a patient.
• suitable indicia whether cancer cell growth is inhibited.
• efficacy of a treatment according to the invention can be measured based on changes in the course of disease in response to a use or a method according to the invention.
• the efficacy can be measured through the measuring of the elicited immune response against cancer cells such as by analyzing tumor-specific T cells or by assessing cancer cell death and/or inhibition of tumor growth, progression and dissemination, reduction of tumour volume, and/or an increase of progression free survival time and/or increased health and well-being of the subject (e.g. repressing a cancer).
• the efficacy of a treatment of a cancer according to the invention can be measured by an inhibition of cancer cell growth evidenced for example by an arrest of cancer cells in a particular phase of the cell cycle, e.g., arrest at the G2/M phase of the cell cycle.
• Inhibition of cancer cell growth can also be evidenced using well known imaging methods such as magnetic resonance imaging, computerized axial tomography, PET, SPECT, photo-acoustic imaging, X-rays and fluorescence imaging/detection.
• Cancer cell growth can also be determined indirectly, for example by determining the levels of circulating carcino-embryonic antigen, prostate specific antigen or other cancer- specific antigens that are correlated with cancer cell growth.
• efficacy of a combined treatment according to the invention can be assessed by expansion of tumor infiltrating CD8+ T cells, reduction of tumour size, disappearance of tumour, survival of tumor bearing mice or of any biomarker relevant for a cancer type.
• “Pharmaceutically active derivative” refers to any compound that upon administration to the recipient, is capable of providing directly or indirectly, the activity disclosed herein.
• the term “indirectly” also encompasses prodrugs which may be converted to the active form of the drug via endogenous enzymes or metabolism.
• the prodrug is a derivative of the compound according to the invention and presenting anti-tumor activity that has a chemically or metabolically decomposable group, and a compound that may be converted into a pharmaceutically active compound in vivo under physiological conditions.
• pharmaceutical formulation refers to preparations which are in such a form as to permit biological activity of the active ingredient(s) to be unequivocally effective and which contain no additional component which would be toxic to subjects to which the said formulation would be administered.
• Fusion proteins IL-10/Fc according to the invention and methods of preparation thereof
• Fc fusion proteins suitable for use in the context of the invention are described herein.
• a Fc fusion protein (IL-10/Fc) according to the invention is a homodimer of two polypeptides, each comprising (i) an immunoglobulin IgG Fc domain and (ii) a heterologous polypeptide a comprising a sequence of a human IL-10 or a variant thereof, wherein the heterologous polypeptide is covalently linked to the N-terminus or the C-terminus of the Fc domain by a polypeptide linker (e.g. a flexible hinge) and the two polypeptides are non-covalently assembled in a homodimer.
• a polypeptide linker e.g. a flexible hinge
• sequence of a Fc fusion protein according to the invention comprises the sequence of a human IL-10, for example wherein said sequence is of SEQ ID NO: 1 or a variant thereof.
• the sequence of a Fc fusion protein according to the invention comprises the sequence of an IgG Fc fragment, wherein said IgG Fc fragment is an IgGl Fc fragment or a variant thereof, in particular a non-cytolytic IgGl Fc.
• a fusion protein IL-10/Fc comprises an IgG Fc fragment of SEQ ID NO: 2 or a variant thereof ⁇ Zheng et ah, 1997, supra; Sazinsky et ah, 2008, Proc. Natl. Acad. Sci. U. S. A. 105, 20167 20172).
• sequence of a Fc fusion protein according to the invention comprises a flexible hinge selected from SEQ ID NO: 3 and a sequence of a GS linker or a variant thereof ⁇ Klein et ah, 2014, supra).
• sequence of a Fc fusion protein according to the invention comprises a flexible hinge selected from SEQ ID NO: 3 and a sequence of GGS linker or a variant thereof ⁇ Klein et ah, 2014, supra).
• sequence of a Fc fusion protein according to the invention comprises a flexible hinge selected from SEQ ID NO: 6 or a sequence of GS linker or a variant thereof.
• sequence of a Fc fusion protein according to the invention comprises a flexible hinge selected from SEQ ID NO: 9 or a sequence of GS linker or a variant thereof.
• sequence of a Fc fusion protein according to the invention comprises a flexible hinge selected from SEQ ID NO: 12 or a sequence of GS linker or a variant thereof.
• sequence a Fc fusion protein according to the invention comprises a sequence of SEQ ID NO: 4 or a variant thereof.
• the sequence of a Fc fusion protein according to the invention comprises the sequence of an IgG Fc fragment, wherein said IgG Fc fragment is an IgG2 Fc fragment or a variant thereof, in particular a non-cytolytic IgG2 Fc.
• a fusion protein IL-10/Fc comprises an IgG Fc fragment of SEQ ID NO: 5 or a variant thereof.
• the sequence a Fc fusion protein according to the invention comprises a sequence of SEQ ID NO: 7 or a variant thereof.
• sequence of a Fc fusion protein according to the invention comprises the sequence of an IgG Fc fragment, wherein said IgG Fc fragment is an IgG3 Fc fragment or a variant thereof.
• a fusion protein IL-10/Fc comprises an IgG Fc fragment of SEQ ID NO: 8 or a variant thereof.
• sequence a Fc fusion protein according to the invention comprises a sequence of SEQ ID NO: 10 or a variant thereof.
• the sequence of a Fc fusion protein according to the invention comprises the sequence of an IgG Fc fragment, wherein said IgG Fc fragment is an IgG4 Fc fragment or a variant thereof.
• a fusion protein IL-10/Fc comprises an IgG Fc fragment of SEQ ID NO: 11 or a variant thereof.
• the sequence a Fc fusion protein according to the invention comprises a sequence of SEQ ID NO: 13 or a variant thereof.
• a Fc fusion protein IL-10/Fc comprises a sequence of a fusion protein IL-10/Fc described in Guo et ah, 2012, supra or in Zheng et al, 1997, ./. Immunol., 158, 4507 4513 or in Steele et ah, 1995, ./. Immunol., 154, 5590 5600 or variants or fragments thereof.
• the Fc fusion proteins IL-10/Fc can be prepared as described herein or as described in Guo et ah, 2012, supra or in Zheng et ah, 1997, supra or in Steele et ah, 1995, supra.
• compositions according to the invention are provided.
• the invention provides pharmaceutical or therapeutic agents as compositions and methods for treating a subject, preferably a mammalian subject, and most preferably a human patient who is suffering from a medical disorder, and in particular a cancer, in particular a solid tumor cancer.
• the invention provides a pharmaceutical composition containing at least one compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient thereof.
• Agent of the invention or formulations thereof may be administered as a pharmaceutical formulation, which can contain one or more agents according to the invention in any form described herein.
• the compositions according to the invention, together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous) use by injection or continuous infusion.
• Injectable compositions are typically based upon injectable sterile saline or phosphate- buffered saline or other injectable carriers known in the art.
• Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
• compositions of this invention may be liquid formulations including, but not limited to aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs.
• the compositions may also be formulated as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations may contain additives including, but not limited to, suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.
• Suspending agents include, but are not limited to, sorbitol syrup, methylcellulose, glucose/sugar syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats.
• Emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia.
• Preservatives include, but are not limited to, methyl or propyl p- hydroxybenzoate and sorbic acid.
• Dispersing or wetting agents include but are not limited to poly(ethylene glycol), glycerol, bovine serum albumin, Tween®, Span®.
• compositions of this invention may also be formulated as a depot preparation, which may be administered by implantation or by intramuscular injection.
• Solid compositions of this invention may be in the form of tablets or lozenges formulated in a conventional manner.
• tablets and capsules for oral administration may contain conventional excipients including, but not limited to, binding agents, fillers, lubricants, disintegrants and wetting agents.
• Binding agents include, but are not limited to, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch and polyvinylpyrrolidone.
• Fillers include, but are not limited to, lactose, sugar, microcrystalline cellulose, maize starch, calcium phosphate, and sorbitol.
• Lubricants include, but are not limited to, magnesium stearate, stearic acid, talc, polyethylene glycol, and silica.
• Disintegrants include, but are not limited to, potato starch and sodium starch glycollate.
• Wetting agents include, but are not limited to, sodium lauryl sulfate. Tablets may be coated according to methods well known in the art.
• composition wherein the sequence of said fusion protein comprises a sequence of SEQ ID NO: 4 or a variant thereof.
• composition wherein the sequence of said fusion protein comprises a sequence of SEQ ID NO: 7 or a variant thereof.
• composition wherein the sequence of said fusion protein comprises a sequence of SEQ ID NO: 10 or a variant thereof.
• composition wherein the sequence of said fusion protein comprises a sequence of SEQ ID NO: 13 or a variant thereof.
• the compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems.
• compositions according to the invention are for intravenous use.
• compositions according to the invention are for intraperitoneal use. According to a particular embodiment, compositions according to the invention are for intratumoral use.
• compositions according to the invention are adapted for delivery by repeated administration.
• compositions of the invention are veterinary compositions.
• compositions of this invention may be administered in any manner including parenterally, intravenously, intra-tumorally, intrathecally, transmucosally, intranasally, rectally, or combinations thereof.
• Parenteral administration includes, but is not limited to, intravenous, intra-arterial, intra-peritoneal, subcutaneous and intramuscular.
• the compositions of this invention may also be administered in the form of an implant, which allows slow release of the compositions as well as a slow controlled i.v. infusion.
• the dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including pharmacokinetic properties, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired.
• compounds of the invention are to be administered in further combination with at least one therapeutic strategy useful in the prevention and/or treatment of a cancer, in particular an anti-cancer immunotherapy such as ACT therapy or immune checkpoint blockade therapy.
• an anti-cancer immunotherapy such as ACT therapy or immune checkpoint blockade therapy.
• the compounds of the invention are to be administered in combination with ACT therapy.
• the compounds of the invention are to be administered in combination with at least one immune checkpoint inhibitor.
• a pharmaceutical composition comprising at least one Fc fusion protein IL-10/Fc and a pharmaceutically acceptable carrier, diluent or excipient thereof and at least one agent useful in ACT therapy.
• a pharmaceutical composition comprising at least one Fc fusion protein IL-10/Fc and a pharmaceutically acceptable carrier, diluent or excipient thereof and at least one immune checkpoint inhibitor.
• the invention encompasses the administration of a compound of the invention or a formulation thereof wherein it is administered to a subject prior to, simultaneously or sequentially with other therapeutic regimens or co-agents useful for preventing, treating, and/or stabilizing a cancer such as anti-cancer treatments.
• a compound of the invention or a formulation thereof according to the invention that is administered simultaneously with said co-agents can be administered in the same or different composition(s) and by the same or different route(s) of administration.
• a pharmaceutical formulation comprising a compound of the invention combined with at least one co-agent useful for treating, and/or stabilizing, a neurodegenerative disorder and at least one pharmaceutically acceptable carrier.
• the invention provides a Fc fusion protein (IL-10/Fc) for use in the prevention and/or treatment of a cancer.
• a Fc fusion protein (IL-10/Fc) for use in anti cancer immunotherapy.
• a Fc fusion protein for use in combination with ACT immunotherapy, in particular based on TCR-T cells or CAR-T cells or TILs therapy.
• the invention provides a method of preventing or treating a cancer, in particular a solid tumor cancer.
• the invention provides a method of preventing and/or treating a lung cancer (small cell and non-small cell), breast cancer, prostate cancer, cancer, ovarian cancer, cervical cancer, uterus cancer, head and neck cancer, glioblastoma, hepatocellular carcinoma, colon cancer, rectal cancer, colorectal carcinoma, kidney cancer, gastric cancer, bronchus cancer, pancreatic cancer, urinary bladder cancer, hepatic cancer and brain cancer skin cancer.
• a lung cancer small cell and non-small cell
• breast cancer breast cancer
• prostate cancer cancer
• cancer ovarian cancer
• cervical cancer uterus cancer
• head and neck cancer glioblastoma
• hepatocellular carcinoma colon cancer
• rectal cancer colorectal carcinoma
• kidney cancer gastric cancer
• bronchus cancer pancreatic cancer
• urinary bladder cancer hepatic cancer and brain cancer skin cancer.
• the invention provides a method of inducing immunity in a subject, said method comprising administering immune check-point blockades, in particular an anti-cancer immune check-point blockades in combination with a Fc fusion protein IL- 10/Fc of the invention in a subject in need thereof.
• the compounds of the invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions (i.e. culture or reaction temperatures, time, moles of reagents, solvents etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by the person skilled in the art, using routine optimization procedures.
• patients according to the invention are suffering from any type of cancer.
• patients according to the invention are suffering from any type of cancer at any stage, including non-metastatic and metastatic.
• patients according to the invention are suffering from lung cancer (small cell and non-small cell), breast cancer, prostate cancer, cancer, ovarian cancer, cervical cancer, uterus cancer, head and neck cancer, glioblastoma, hepatocellular carcinoma, colon cancer, rectal cancer, colorectal carcinoma, kidney cancer, gastric cancer, bronchus cancer, pancreatic cancer, urinary bladder cancer, hepatic cancer and brain cancer or skin cancer.
• lung cancer small cell and non-small cell
• breast cancer breast cancer
• prostate cancer cancer
• cancer ovarian cancer
• cervical cancer uterus cancer
• head and neck cancer glioblastoma
• hepatocellular carcinoma colon cancer
• rectal cancer colorectal carcinoma
• kidney cancer gastric cancer
• bronchus cancer pancreatic cancer
• urinary bladder cancer hepatic cancer and brain cancer or skin cancer.
• patients according to the invention are suffering from skin, breast, prostate, lung, pancreas, esophageal, hepatocellular, ovarian, colorectal and head and neck cancer and other solid tumors or any pre-malignant or malignant neoplasm.
• patients according to the invention are suffering from melanoma.
• subjects according to the invention are suffering from or at risk of suffering from a cancer.
• Compounds, compositions and methods according to the invention are particularly useful for enhancing pyruvate dependent OXPHOS in CD8+ T cells and therefore in combination with immunotherapies such as those described therein.
• IL-10 and IgGl Fc fusion protein (IL-lO/Fc of SEQ ID NO: 4) (Fig. la) which could cross-react with mouse or human IL-10 receptor (IL-10R) through IL-10 domain of the IL-10/Fc fusion protein was processed (Qiao et ah, 2019, Cancer Cell 35, 901 915.e4). Therefore, the IL-10/Fc fusion protein could work on both mouse and human CD8+ T cells.
• the IL-10/Fc fusion protein was expressed by HEK293 free style cells using the commercial mammalian expression vector, such as pcDNA3.1 or pSectag2A, carrying IL-10/Fc fusion gene as described before in Guo et ah, 2012, supra or in Zheng et ah, 1997, J. Immunol., 158, 4507 4513 or in Steele et ah, 1995, J. Immunol., 154, 5590 5600 and then the culture supernatant containing IL-10/Fc was harvested by centrifuge after 7-day culture.
• the commercial mammalian expression vector such as pcDNA3.1 or pSectag2A
• the IL-10/Fc fusion protein was first captured by Protein A column and then further purified by Superdex 200 increase column.
• the purified IL-10/Fc fusion protein was aliquoted and stored in -80 °C for stock.
• the purity of IL-10/Fc reached to 95% evidenced by SDS-PAGE and HPLC analysis.
• a HiTrap Protein A affinity chromatography column was used to capture the recombinant IL-10/Fc from the clarified expression supernatant filtered through 0.22-pm membranes, washed with 5 column volume binding buffer, and eluted with elution buffer (0.05 M sodium citrate, 0.3 M NaCl, pH 3.0).
• the eluted protein was immediately collected into neutralization buffer (1.0 M Tris-HCl, pH 10.0).
• neutralization buffer 1.0 M Tris-HCl, pH 10.0.
• the eluted protein was concentrated by 10 kDa membrane ultrafiltration (Vivaspin) and further purified with Superdex 200 increase size-exclusion chromatography at a flow rate of 1.0 mL/min with PBS, and the purified protein was aliquoted and stored at -80 °C.
• Example 2 Role of a fusion protein IL-10/Fc of the invention in IL-10-mediated metabolic reprograming
• a fusion protein of the invention is able to reprograms T cells metabolism to promote T cell proliferation by increasing OXPHOS upon TCR stimulation through a pyruvate-dependent manner which may indicate that fusion protein of the invention could also promote tumor reactive CD8+ T cell expansion in the TME through reprograming T cells metabolism.
• Example 3 In-vivo anti tumoral effects of a fusion protein of the invention
• Enhancing OXPHOS or inhibiting glycolytic metabolism in CD8+ T cells by various reagents promoted CD8+ T cell proliferation, memory development and antitumor function in TME ⁇ Zhang et ah, 2017, Cancer Cell 32, 377 391. e9; Chowdhury et ah, 2018, Cancer Immunol. Res. 6, 1375 1387; Sukumar et al., 2013, 123, 4479 4488).
• Based on the observed metabolic regulation function of the Fc fusion protein of the invention on CD8+ T-cells investigating whether in vivo metabolic intervention of CD8 T-cells can be achieved with IL-10/Fc in view of enhancing the efficacy of adoptive T cell immunotherapies against solid tumors.
• TCR transgenic CD8+ T cells Pmel CD8+ T cell or OTI CD8+ T cells
• HER2 CAR-T cells in several tumor models, such as B16F10 (poorly immunogenic, highly aggressive mouse melanoma model), YTJMMl.7-OVA (mouse melanoma model), or MC-38- HER2 (mouse colon carcinoma), respectively.
• IL-10/Fc treatment was combined with OT- I CD8+ T-cells in the treatment of an OVA-expressing mouse melanoma model (YTJMMl.7- OVA) ⁇ Meeth et al, 2016, Pigment Cell Melanoma Res. 29, 590 597; Lane et al, 2018, J. Exp. Med. 215, 3057 3074).
• Tumor cells (1 million tumor cells per mouse) were inject s.c. and allowed to grow to high tumor burden (size > 60 mm2 or 150 mm3) (Pai et al, 2019, Immunity, 50, 477 492. e8) before the initiation of therapy.
• CAR-T chimeric antigen receptor T
• MC-38 a murine colon adenocarcinoma that expresses human epidermal growth factor receptor 2 (HER2).
• HER2 human epidermal growth factor receptor 2
• a fusion protein of the invention is able to potentiate adoptive T cells therapy by promoting T cell mediated tumor regression in both syngeneic and xenograft mouse models with pre-established solid tumors to eradicate established tumors.
• Example 4 In-vivo role of a fusion protein of the invention on immune infiltration of tumors
• B16F10 tumor cells (1 c 10 6 ) were inoculated subcutaneously in C57B1/6 mice and allowed to establish tumor for 6 d. Mice were then received PBS, IL-10/Fc, single adoptive transfer of 5 x 10 6 activated pmel-1 CD8+ T cells (ACT) or IL-10/Fc and ACT combination therapy (combo) on day 6. Mice were received 4 injections of IL-10/Fc or PBS as indicated in experimental scheme. Mice were then sacrificed on day 14 and TILs were analyzed by flow cytometry.
• ACT activated pmel-1 CD8+ T cells
• combo ACT combination therapy
• IL-10/Fc significantly increased tumor infiltrating T cells, in particular CD8+ T cells, in TME (Fig. 6a), but not natural killer (NK) cells or dendritic cells (DCs) (Fig. 5b), in the group treated with combination therapy compared with ACT alone.
• the results were confirmed with immunofluorescence staining of tumor sections (Fig. 6b).
• IL-10/Fc significantly decreased the percentage of Treg and increased the ratio CD8+ / Treg cells in TME (Fig. 5c).
• IL-10/Fc treatment also markedly enhances the polyfunctions of both endogenous and adoptively transferred Pmel CD8+ T cells in tumors (Fig. 6h).
• TILs isolated from tumor tissues were stained by anti mouse CD45.2, CD4, CD8, PD-1, and TIM-3 fl orescent antibodies, and then analysed by FACS assay. It has been reported recently that the PD-1+TIM-3+CD8+T cells previously defined as exhausted are in fact a highly proliferating, clonal, and dynamically differentiating cell population within the human tumor microenvironment with high cytotoxicity ( Miller et al, 2019, Nat. Immunol.
• IL-10/Fc treatment significantly increased the portion of PD-l+Tim-3+ subsets among CD8+ T cells with the similar phenotype of “exhausted T cell” (Fig. 6c).
• IL-10/Fc selectively expanded PD-l+Tim-3+ but not other subsets in both endogenous (5.9 fold) and adoptively transferred Pmel CD8+ T cells (12.9 fold) in tumors (Fig. 6d and e). Consistent with this observation, IL-10 receptor expression was highly upregulated on PD-l+Tim-3+CD8+ T subsets in the TME (Fig. 6f).
• PD-l+Tim-3+ subset was conventionally considered as “exhausted T-cells”, we noticed that this subset in the combination treatment group showed decreased PD-1 expression level in both endogenous and Pmel CD8+ T cells (Fig. 6g), which may indicate reinvigoration of effector functions. Consistent with speculation, ploy functional effector cells among the PD-1+TIM-3+CD8+ T cell subsets were greatly increased with IL-10/Fc treatment (Fig. 6i). High percentage of the intratumoral PD-l+Tim-3+ CD8+ T cell exhibit high cytotoxicity and proliferative capacity (Fig. 6j and k). Further analysis show that PD-1+ Tim- 3+ CD8+ T cells acquire memory phenotype in central lymphoid organs, which may contribute to memory CD8+ T cell development (Fig. 61).
• the OCR of the PD-l+Tim-3+CD8+ T subset was significantly increased by treatment of IL-10/Fc (Fig. 6m), which indicated that the PD-l+Tim-3+CD8+ T subset preferentially used OXPHOS over glycolysis after metabolic reprograming by IL-10/Fc.
• IL-10/Fc also enhanced the performance of checkpoint blockade therapy against the established solid tumor in mice (Fig. 7).
• Combination therapy of IL-10/Fc and a-PD-1 antibody significantly inhibited the tumor growth and promoted the survival of CT-26 tumor bearing mice (Fig. 7b-d).
• a Fc fusion protein of the invention provides a novel metabolic intervention strategy for highly effective ACT cancer immunotherapy against solid tumors such as TCR-T, CAR-T as well as TILs isolated from tumor tissues for personized cancer immunotherapy. Further, based on those data, the use of a Fc fusion protein of the invention is considered as a safe and potent possible enhancer for immune check-point blockade therapy.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Toxicology (AREA)
• Biophysics (AREA)
• Cell Biology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Developmental Biology & Embryology (AREA)
• Virology (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=68069476

Family Applications (1)

Country Status (10)

Cited By (1)

Families Citing this family (3)

Citations (3)

Family Cites Families (11)

• 2019
  • 2019-09-19 EP EP19198358.4A patent/EP3795583A1/en not_active Withdrawn
• 2020
  • 2020-09-18 US US17/760,947 patent/US20220370564A1/en active Pending
  • 2020-09-18 WO PCT/EP2020/076089 patent/WO2021053134A1/en not_active Ceased
  • 2020-09-18 CN CN202080076692.1A patent/CN114728041A/zh active Pending
  • 2020-09-18 JP JP2022516618A patent/JP7822620B2/ja active Active
  • 2020-09-18 EP EP20771582.2A patent/EP4031564A1/en active Pending
  • 2020-09-18 MX MX2022003417A patent/MX2022003417A/es unknown
  • 2020-09-18 BR BR112022005159A patent/BR112022005159A2/pt unknown
  • 2020-09-18 KR KR1020227013049A patent/KR20220065839A/ko active Pending
  • 2020-09-18 CA CA3150050A patent/CA3150050A1/en active Pending
  • 2020-09-18 AU AU2020351062A patent/AU2020351062B2/en active Active

Patent Citations (3)

Non-Patent Citations (51)

Also Published As

Similar Documents

Legal Events